| Identification | Back Directory | [Name]
FOSINOPRILAT | [CAS]
95399-71-6 | [Synonyms]
SQ-27519
Fosfenopril
Fospenopril
FOSINOPRILAT
Forsinoprilat
Fosinoprilat-D5
fosinoprilicacid
SQ 27519 Disodium Salt
Fosinopril EP Impurity A
Fosfenopril Disodium Salt
Fosinoprilat Disodium Salt
Fosinoprilic Acid Disodium Salt
Fosinoprilat (Fosinopril IMpurity B)
4β-Cyclohexyl-1-[[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-L-proline
L-Proline, 4-cyclohexyl-1-hydroxy(4-phenylbutyl)phosphinylacetyl-, (4S)-
(4S)-4-Cyclohexyl-1-{[hydroxy(4-phenylbutyl)phosphinyl]acetyl}-L-proline
(4S)-4-Cyclohexyl-1-[2-[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-L-proline Disodium Salt
Fosinopril Related Compound A (25 mg) ((4S)-4-cyclohexyl-[(4-phenylbutyl)phosphinyl]acetyl-L-proline) | [Molecular Formula]
C23H34NO5P | [MDL Number]
MFCD00865781 | [MOL File]
95399-71-6.mol | [Molecular Weight]
435.49 |
| Chemical Properties | Back Directory | [Appearance]
White Crystalline Solid | [Melting point ]
>3000C | [alpha ]
D -24° (c = 1 in methanol) | [Boiling point ]
728.9±60.0 °C(Predicted) | [density ]
1.238±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
Methanol (Slightly), Water (Slightly) | [form ]
Solid | [pka]
2.75±0.50(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Chemical Properties]
White Crystalline Solid | [Uses]
A metabolite of Fosinopril, a phosphinic acid containing angiotensin converting enzyme (ACE) inhibitor | [Definition]
ChEBI: A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of
ypertension and chronic heart failure. | [in vivo]
Fosfenopril (0.5 mg/kg bolus plus 0.1 mg/kg/min, IV, once) increases p-aminohippurate (PAH) clearance and glomerular filtration rate (GFR) in dogs[3]. | Animal Model: | Famale mongrel dogs (n=7)[3] | | Dosage: | 0.5 mg/kg (1.1 mumol/kg) bolus plus 0.1 mg/kg/min (0.22 mumol/kg/min) | | Administration: | IV, once | | Result: | Increased p-aminohippurate (PAH) clearance and glomerular filtration rate (GFR) by 25 and 16%, respectively without changing arterial pressure (AP). |
| [IC 50]
TLR4; NF-κB; IL-6; IL-1β |
|
| Company Name: |
TOSUN PHARM
|
| Tel: |
020-61855200 13326451905 |
| Website: |
www.toref.cn/ |
|